Respiratory Viral Infections-Focused Revelation Biosciences Turns To SPAC Deal For NASDAQ Debut
Respiratory Viral Infections-Focused Revelation Biosciences Turns To SPAC Deal For NASDAQ Debut
专注于呼吸道病毒感染的揭示生物科学公司转向SPAC交易，首次亮相纳斯达克
- Revelation Biosciences Inc is joining Petra Acquisition Inc (NASDAQ: PAIC) to create a NASDAQ-listed company with an enterprise value of $128 million.
- The merger is expected to close in Q4 2021, and the combined company will be listed on NASDAQ under the ticker symbol REVB.
- Revelation will pocket $73 million through the merger and use the money to advance REVTx-99, a nasal drop formulation designed to stimulate the innate immune system via TLR4-TRIF pathway agonism.
- In a 48-subject phase 1 trial, Revelation linked REVTx-99 to increased intranasal levels of the cytokine IP-10.
- Revelation identified IP-10 as the key cytokine of interest because it is upregulated in response to respiratory viral infection and linked to clinical efficacy in challenge studies.
- With phase 1 proof-of-principle data in hand, Revelation is now gearing up for further development.
- A 60-subject phase 2 influenza viral challenge study is slated to start in Q1 of 2022.
- REVTx-99 is also in development to treat chronic nasal congestion, with a phase 1 trial set to start this year.
- The same platform has generated a second, earlier-stage candidate, REVTx-200. Revelation sees the follow-up prospect as a way to improve the immune response to intramuscular vaccines.
- Price Action: PAIC stock is up 0.05% at $10.06 during the market session on the last check Monday.
- 启示录生物科学公司正在加入Petra Acquisition Inc.(纳斯达克： 中国石油天然气集团公司(PAIC：行情)创建一家纳斯达克上市公司，企业价值1.28亿美元.
- 合并预计将于2021年第四季度完成，合并后的公司将在纳斯达克上市，股票代码为REVB。
- 启示会将通过合并获得7300万美元，并将这笔钱用于推进REVTx-99，这是一种滴鼻剂，旨在通过TLR4-TRIF途径激动剂刺激先天免疫系统。
- 在48名受试者的第一阶段试验中，发现REVTx-99与鼻腔内细胞因子IP-10水平升高有关。
- 启示录确认IP-10是重要的细胞因子，因为它在应对呼吸道病毒感染时上调，并与挑战研究中的临床疗效有关。
- 有了第一阶段的原则证明数据，启示录现在正在为进一步的发展做准备。
- 一项由60名受试者组成的第二阶段流感病毒挑战研究定于2022年第一季度开始。
- REVTx-99也在开发中，用于治疗慢性鼻塞，第一阶段试验将于今年开始。
- 同一个平台已经产生了第二个更早阶段的候选者REVTx-200。启示录认为，后续的前景是改善对肌肉内疫苗的免疫反应的一种方式。
- 价格行动：在周一最后一次检查的市场时段，Paic股价上涨0.05%，至10.06美元。